USE OF MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR IN THE TREATMENT OF PATIENTS WITH ACUTE HYPOXAEMIC RESPIRATORY FAILURE

The present invention relates to the fields of biotechnology and medicine. The invention relates to the use of monoclonal antibodies directed against the epidermal growth factor receptor in the treatment of diseases of infectious origin where acute hypoxaemic respiratory failure occurs. La présente...

Full description

Saved in:
Bibliographic Details
Main Authors LEON MONZON, KALET, RAMOS SUZARTE, MAYRA, DIAZ LONDRES, HENRRY, SAAVEDRA HERNANDEZ, DANAY, ABDO CUZA, ANSELMO ANTONIO, ROLANDO, PEREZ RODRIGUEZ, ANE KOURI, ANA LAURA, CROMBET RAMOS, TANIA, JIMENEZ ARMADA, JORGE
Format Patent
LanguageEnglish
French
Published 22.12.2022
Subjects
CHEMISTRY
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
Online AccessGet full text

Cover

More Information
Summary:The present invention relates to the fields of biotechnology and medicine. The invention relates to the use of monoclonal antibodies directed against the epidermal growth factor receptor in the treatment of diseases of infectious origin where acute hypoxaemic respiratory failure occurs. La présente invention concerne les domaines de la biotechnologie et de la médecine. Elle décrit l'utilisation d'anticorps monoclonaux dirigés contre le récepteur du facteur de croissance épidermique dans le traitement de maladies d'origine infectieuse dans lesquelles se produit une insuffisance respiratoire aiguë hypoxémique.
Bibliography:Application Number: CA20223222462